STRATIFYER Molecular Pathology GmbH


Industrie / privates Unternehmen

Standort der Organisation:
Köln, Deutschland


Publikationen in Kooperation mit FAU-Wissenschaftlerinnen und Wissenschaftlern


Go to first page Go to previous page 1 von 2 Go to next page Go to last page
Erben, P., Sikic, D., Wirtz, R.M., Martini, T., Weis, C.-A., Breyer, J.,... Bolenz, C. (2019). Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Archiv, 474(2), 209–217. https://dx.doi.org/10.1007/s00428-018-2496-9
Sikic, D., Wirtz, R.M., Wach, S., Dyrskjot, L., Erben, P., Bolenz, C.,... Keck, B. (2019). Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Translational Oncology, 12(4), 661-668. https://dx.doi.org/10.1016/j.tranon.2019.01.005
Martini, T., Heinkele, J., Mayr, R., Weis, C.-A., Wezel, F., Wahby, S.,... Erben, P. (2019). Erratum to 'Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy' [Urologic Oncology: Seminars and Original Investigations 36/12 (2018) 505-534]. Urologic Oncology-Seminars and Original Investigations, 37(3), 227-227. https://dx.doi.org/10.1016/j.urolonc.2018.12.019
Breyer, J., Wirtz, R.M., Erben, P., Rinaldetti, S., Worst, T.S., Stoehr, R.,... Otto, W. (2019). FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. Bju International, 123(1), 187-196. https://dx.doi.org/10.1111/bju.14525
Busse, A., Spenke, C., Arsenic, R., Briest, F., Sipos, B., Kaemmerer, D.,... Grabowski, P. (2019). Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy. In NEUROENDOCRINOLOGY (pp. 5-5). BASEL: KARGER.
Eckstein, M., Erben, P., Kriegmair, M.C., Worst, T.S., Weiss, C.-A., Wirtz, R.M.,... Erlmeier, F. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer, 106, 234-243. https://dx.doi.org/10.1016/j.ejca.2018.11.007
Pfannstiel, C., Strissel, P., Chiappinelli, K.B., Sikic, D., Wach, S., Wirtz, R.M.,... Eckstein, M. (2019). The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunology Research, 7(6), 923-938. https://dx.doi.org/10.1158/2326-6066.CIR-18-0758
Baur, V., Papadopoulos, T., Kazakov, D., Agaimy, A., Hartmann, A., Isbary, G.,... Schultz, E.S. (2018). A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib. Virchows Archiv, 473(2), 241-246. https://dx.doi.org/10.1007/s00428-018-2397-y
Eckstein, M., Wirtz, R., Pfannstil, C., Wach, S., Stoehr, R., Breyer, J.,... Erben, P. (2018). A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany. (pp. 81-81).
Sikic, D., Wirtz, R., Wach, S., Dyrskjot, L., Erben, P., Bolenz, C.,... Keck, B. (2018). Analysis of androgen receptor mRNA expression in urothelial carcinoma of the bladder. (pp. 70-70).
Worst, T.S., Weis, C.-A., Stoehr, R., Bertz, S., Eckstein, M., Otto, W.,... Erben, P. (2018). CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Scientific Reports, 8(1). https://dx.doi.org/10.1038/s41598-018-32569-x
Fasching, P., Laible, M., Weber, K.E., Wirtz, R.M., Denkert, C., Schlombs, K.,... Untch, M. (2018). Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes. In ANNALS OF ONCOLOGY (pp. 73-73). Munich, DE: OXFORD: OXFORD UNIV PRESS.
Rinaldetti, S., Wirtz, R., Worst, T.S., Hartmann, A., Breyer, J., Dyrskjot, L., & Erben, P. (2018). FOXM1 predicts disease progression in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 144(9), 1701-1709. https://dx.doi.org/10.1007/s00432-018-2694-5
Breyer, J., Wirtz, R.M., Erben, P., Worst, T.S., Stoehr, R., Eckstein, M.,... Otto, W. (2018). High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Clinical Genitourinary Cancer. https://dx.doi.org/10.1016/j.clgc.2018.01.009
Breyer, J., Wirtz, R.M., Otto, W., Erben, P., Worst, T.S., Stoehr, R.,... Hartmann, A. (2018). High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunology, Immunotherapy, 67(3), 403-412. https://dx.doi.org/10.1007/s00262-017-2093-9
Eckstein, M., Wirtz, R.M., Gross-Weege, M., Breyer, J., Otto, W., Stoehr, R.,... Erben, P. (2018). mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. International Journal of Molecular Sciences, 19(11). https://dx.doi.org/10.3390/ijms19113396
Fasching, P., Laible, M., Weber, K.E., Wirtz, R.M., Denkert, C., Schlombs, K.,... Untch, M. (2018). Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC). In ANNALS OF ONCOLOGY (pp. 53-53). Munich, GERMANY: OXFORD: OXFORD UNIV PRESS.
Erber, R., Stoehr, R., Herlein, S., Giedl, C., Rieker, R., Fuchs, F.,... Brueckl, W.M. (2017). Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Research, 37(12), 6771-6778. https://dx.doi.org/10.21873/anticanres.12137
Erber, R., Stoehr, R., Herlein, S., Fuchs, F., Veltrup, E., Wirtz, R., & Hartmann, A. (2017). Comparison of PD-L1 mRNA expression measured with the CheckPointTyper(R) assay with PD-L1 protein expression assessed with immunohistochemistry (IHC) in lung cancer (NSCLC). (pp. S102-S102).
Breyer, J., Otto, W., Wirtz, R.M., Wullich, B., Keck, B., Erben, P.,... Hartmann, A. (2017). ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urologia Internationalis, 98(3), 282-289. https://dx.doi.org/10.1159/000453670

Zuletzt aktualisiert 2017-01-06 um 08:26